AlloVir ( NASDAQ:ALVR – Get Rating ) and Biogen ( NASDAQ:BIIB – Get Rating ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability. Risk & Volatility AlloVir has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

https://www.dailypolitical.com/2023/03/04/head-to-head-analysis-allovir-nasdaqalvr-versus-biogen-nasdaqbiib.html

#dailypolitical